Pazopanib and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with pazopanib.
Pazopanib Food/Lifestyle
Major Food Interaction
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of pazopanib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Although not studied, the interaction may increase the risk of QT interval prolongation and torsade de pointes arrhythmia as well as severe and fatal hepatotoxicity associated with the use of pazopanib.
ADJUST DOSING INTERVAL: Food increases the oral bioavailability of pazopanib. The mechanism of interaction is unknown. Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold increase in peak plasma concentration (Cmax) and systemic exposure (AUC).
MANAGEMENT: Patients treated with pazopanib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract. Pazopanib should be administered at least one hour before or two hours after a meal.
References (1)
- (2009) "Product Information. Votrient (pazopanib)." GlaxoSmithKline
Switch to consumer interaction data
Pazopanib drug interactions
There are 704 drug interactions with pazopanib.
Pazopanib disease interactions
There are 11 disease interactions with pazopanib which include:
- bleeding
- liver dysfunction
- GI perforation
- CV disease
- hypothyroidism
- lung dysfunction
- QT prolongation
- hypertension
- PRES
- proteinuria
- thromboembolic disorders
More about pazopanib
- pazopanib consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (92)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: VEGF/VEGFR inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Votrient
Votrient is used to treat renal cell carcinoma (kidney cancer). Learn about side effects ...
Caplyta
Caplyta is used to treat schizophrenia or depression associated with bipolar disorder. It is taken ...
Yondelis
Yondelis (trabectedin) is used to treat liposarcoma or leiomyosarcoma, two common subtypes of soft ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Tecentriq Hybreza
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is a subcutaneous formulation of Tecentriq ...
Atezolizumab/hyaluronidase
Atezolizumab/hyaluronidase is used for alveolar soft part sarcoma, hepatocellular carcinoma ...
Atezolizumab
Atezolizumab (Tecentriq) is a type of immunotherapy drug that helps the body's immune system to ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.